These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25894088)

  • 41. Statistical methods for assessing interchangeability of biosimilars.
    Chow SC; Yang LY; Starr A; Chiu ST
    Stat Med; 2013 Feb; 32(3):442-8. PubMed ID: 22899372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Key considerations in the preclinical development of biosimilars.
    Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
    Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
    Kirsch-Stefan N; Guillen E; Ekman N; Barry S; Knippel V; Killalea S; Weise M; Wolff-Holz E
    BioDrugs; 2023 Nov; 37(6):855-871. PubMed ID: 37831324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.
    Vezér B; Buzás Z; Sebeszta M; Zrubka Z
    Curr Med Res Opin; 2016 May; 32(5):829-34. PubMed ID: 26808864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilars: Hope and concern.
    Emmanouilides CE; Karampola MI; Beredima M
    J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario.
    Pipalava P; Patel R; Mehta M; Dahiya M; Singh I; Jose V
    Regul Toxicol Pharmacol; 2019 Oct; 107():104415. PubMed ID: 31254556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
    Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
    Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immunogenicity of biosimilars].
    van Aerts LA; Franken AA; Leufkens HG
    Ned Tijdschr Geneeskd; 2016; 160():D888. PubMed ID: 28000573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges].
    Ferreira Neto PTP; Nunes PHC; Vargas MA
    Cad Saude Publica; 2019; 35(10):e00053519. PubMed ID: 31618379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Main concepts on bioequivalence and biosimilarity in the Chilean legislation, and current controversies on drug interchangeability.
    Stojanova J; Lutz M; Lazcano G; Arancibia M
    Medwave; 2020 Feb; 20(2):e7825. PubMed ID: 32119654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
    Tóthfalusi L; Endrényi L; Chow SC
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.